Precigen

GenVec, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform. The company's lead product candidate, CGF166, is currently undergoing Phase I/II clinical trials aimed at treating hearing loss and balance disorders. Additionally, GenVec is working on GV2311, a vaccine for respiratory syncytial virus, and GV2207, targeting herpes simplex virus. The company collaborates with prominent organizations, including Novartis and Merial, to advance its product pipeline, which encompasses various infectious diseases and animal health concerns. Notably, GenVec is also engaged with the National Institute of Allergy and Infectious Diseases and the Laboratory of Malaria Immunology and Vaccinology to develop malaria vaccine candidates. Founded in 1992, GenVec has established a diverse array of partnerships to support its mission of addressing significant health challenges through innovative gene-based medicine.

EnviroFlight, LLC is a company based in Maysville, Kentucky, that specializes in producing sustainable animal and plant nutrition products by utilizing black soldier fly larvae to process waste materials, such as distillers grains and co-products from breweries and food production. Founded in 2009, the company offers a range of products including EnviroBug, EnviroMeal, EnviroOil, and EnviroFrass, which are designed for use in poultry, aquaculture, pets, and zoo animals, as well as serving as fertilizers. EnviroFlight aims to promote transformative change in the global food supply by developing nutrient sources that are socially responsible, free of toxins and antibiotics, and environmentally sustainable, thereby addressing the financial and ecological costs associated with traditional food production methods. EnviroFlight operates as a subsidiary of Darling Ingredients Inc.

Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002, the company employs proprietary genetic technology to enhance the effectiveness and safety of pest control methods, particularly the Sterile Insect Technique (SIT). Oxitec's products include various genetically modified strains of insects, such as the Aedes aegypti mosquito and the Diamondback moth, designed to reduce populations of disease-carrying and crop-damaging species. These strains are engineered for specific environments in Asia and Latin America and include features like female lethality and fluorescent markers for easy identification. With a mosquito production facility in Brazil, Oxitec aims to provide sustainable, non-toxic alternatives for pest management, thereby contributing to global health and agricultural productivity while minimizing environmental impact.

ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Histogenics Corporation, founded in 2000 and headquartered in Waltham, Massachusetts, is a regenerative medicine company specializing in the development and commercialization of therapeutic medical products for musculoskeletal conditions. The company's innovative platform integrates cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to address cartilage damage and improve joint function. Its primary investigational product, NeoCart, is a tissue implant designed to treat cartilage injuries in the knee, aiming to regenerate healthy cartilage and enhance overall joint performance. In 2019, Histogenics was acquired by Ocugen, Inc., marking a significant transition in its corporate structure.

Medistem, established in 2005, focuses on developing and commercializing adult stem cell-based therapies. The company has built a robust portfolio, including 16 families of patent applications and numerous scientific publications. It has also out-licensed certain technologies to generate revenue. Medistem's primary product is the Endometrial Regenerative Cell (ERC), a universal donor pluripotent stem cell. This innovative therapy is being developed for critical limb ischemia, an advanced form of peripheral artery disease. The ERC aims to promote new blood vessel formation, reduce inflammation, regulate immune system function, and enhance tissue repair and healing. Medistem operates on a fee-for-service basis, leveraging its expertise in adult stem cell applications.

Immunologix, Inc. is a biotechnology company specializing in the development and production of antibody-based therapeutics targeting a range of biological entities. Established in 2008 and located in Charleston, South Carolina, the company focuses on creating human monoclonal antibodies that address viral, bacterial, and tumor antigens, in addition to human autoantigens. Immunologix employs advanced technology to transform naïve B-cells, obtained from sources such as tonsillectomies or whole blood collections, into fully mature human B-cells capable of producing specific human antibodies. This innovative approach positions the company to address various medical needs through targeted therapeutic solutions.

Agarigen is a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.